New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 10, 2023 - Pfizer announced the FDA approval of Zavzpret (zavegepant), for the acute treatment of migraine with or without aura in adults.
Download PDF
Return to publications
